Allogene Therapeutics Inc at B Riley Securities Oncology Conference (Virtual) Transcript
Okay. Good morning, everyone, and welcome to B. Riley's Oncology Conference. I'm Kalpit Patel, a research analyst here at B. Riley. And it's my pleasure to introduce our first fireside chat of the day, with Allogene's CFO, Eric Schmidt.
If anyone in the audience has any questions for Eric, please feel free to e-mail me at [email protected].
Eric, it's great to have you join us today. Welcome.
Questions & Answers
Maybe to start, let's dive right into the data that you've showed at your November R&D showcase. I want to specifically dig into the durability data that you've shown for ALLO-501, 501A. There was a nice slide in there with the swimmers plot that was outlined, which essentially showed how patients performed over a long period of time, the patients who achieved a CR.
Can you give us a sense of how closely this durability
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |